|Seed, 6/2011 ||$500k|
Airway Therapeutics is an early stage development company that is licensing technology from within the pulmonary research program of Cincinnati Childrenâ€™s Hospital Medical Center (CCHMC) for further technology â€˜platformâ€™ development. This platform will enable the development of three or more products that address various market needs in the overall market for lung disorders.
A deficiency of Surfactant Protein D (SP-D) within the lungs is a major contributor to certain lung disorders. SP-D, a naturally occurring protein, is known to provide a key role in proper lung function and in protection against pulmonary infection and inflammation. The initial products for development are based on recombinant human surfactant protein D (rhSP-D), and include two products for the prevention of bronchopulmonary dysplasia (BPD) and one product for the treatment of pulmonary infections associated with cystic fibrosis (CF). Ultimately, we believe that rhSP-D can be used to treat other pulmonary infections and inflammation as well.